-
Medical insurance negotiations are not a "life and death" for innovative drugs
Time of Update: 2021-12-05
Hu Shanlian specifically mentioned that one of the highlights of pharmacoeconomics calculations is that in order to solve the balance between high-priced innovative negotiated drugs and future medical insurance funds, the budget impact analysis of new drugs that may be brought into the catalog is estimated .
-
Accurate, multiple and standardized, alleviate the burden of medical expenses for major diseases
Time of Update: 2021-12-05
The high medical expenses of major diseases are undoubtedly a risk factor for patients and their families to become poor due to illness and return to poverty due to illness. It is also a huge stone
-
Approved 4 companies annually!
Time of Update: 2021-12-05
Zhejiang Hisun Pharmaceuticals Jiangsu Hausen, Yangtze River, Chia Tai Tianqing Qilu Pharmaceuticals, Chongqing Yaoyou Pharmaceuticals, Livzon Group, Hunan Dongting Pharmaceuticals, Shijiazhuang Siyao Chenxin Pharmaceuticals Overview of the layout of Lurasidone related preparations Data source: Yaorongyun drug review database; China clinical trial database In addition, Jinan Benro Pharmaceutical applied for approval for a Class 3.
-
New Deals frequently come out, 6-picture analysis of the API market
Time of Update: 2021-12-05
171 patents will expire, so a large number of generic drugs will be launched in the next few years, and the demand for corresponding APIs will increase accordingly .
-
Notice on Public Solicitation of "Guiding Principles for Evaluation of Immune-Related Adverse Events in Anti-tumor Therapy (Draft for Comment)"
Time of Update: 2021-12-05
pdf 2 "Technical Guidelines for Evaluation of Immune-related Adverse Events in Anti-tumor Therapy (Draft for Comment)" feedback form.
docx2 "Technical Guidelines for Evaluation of Immune-related Adverse Events in Anti-tumor Therapy (Draft for Comment)" feedback form.
-
Looking at the domestically produced original innovative drugs that have been approved in the past four years: the number of approved drugs is increasing year by year
Time of Update: 2021-12-05
In addition, there are currently 4 third-generation EGFR-TKI inhibitors in China (ie Avitinib from Aisen Pharmaceutical, Befortinib from Betta Pharmaceuticals, Rezetinib and Osaikang from Beierda Pharmaceuticals) The industry’s ASK120067) has been reported for production, and more than 10 models are in clinical trials .
-
How does the market view the future of medicine?
Time of Update: 2021-12-05
From Q1 to Q3 of 2021, the revenue and profit of listed companies in the pharmaceutical sector have shown a relatively stable growth trend, and the performance growth rate of the first three quarters has rebounded year-on-year .
-
Across 19 provinces, 76 large varieties are facing big exams... Is it still far for the national centralized procurement of Chinese patent medicines?
Time of Update: 2021-12-05
At the same time, Niu Ben also believes that the "double envelope" adopted by the Hubei Alliance for the centralized procurement of Chinese patent medicines, based on the comprehensive scores and the rules of enterprise competition, also makes price reduction not the only criterion for winning bids.
-
What role can charity play in a multi-level medical security system?
Time of Update: 2021-12-05
To further improve the medical insurance and assistance system for major and serious diseases, it is necessary to use modern governance methods to accelerate the improvement of the multi-level medical security system, make better use of the market, charity and other forces, form a basis for relying on government guarantees, and activate commercial resources to intervene and mobilize A comprehensive security pattern involving the participation of social forces .
-
Domestic drugs accelerate their entry into the Parkinson's disease market!
Time of Update: 2021-12-05
In 2020, the amount of anti-Parkinson's disease drugs used in public hospitals in key provinces and cities in China reached 620 million yuan, an increase of 8.
-
Express US$3.3 billion to accelerate RNAi therapy development, Novo Nordisk will acquire Dicerna
Time of Update: 2021-12-05
This acquisition will accelerate Novo Nordisk's RNAi drug development and expand the application of RNAi technology .
com/news-releases/news-release-details/novo-nordisk-acquire-dicerna Original English: https://investors.
com/news-releases/news-release-details/novo-nordisk-acquire-dicerna
-
With revenue of 100 million and an area of 200 square meters, are the requirements for "dual channel" pharmacies reasonable?
Time of Update: 2021-12-05
For example, Handan, Hebei requires that the business area of "dual channel" pharmacies is not less than 200 square meters, and the annual drug revenue should exceed 100 million yuan.
-
[Latest blockbuster] The Ministry of Finance formulated and issued the "Specific Guidelines on Cost Accounting for Public Institutions-Public Hospitals"
Time of Update: 2021-12-05
In order to serve the needs of the current hospitals for price supervision of medical services and payment method reforms, the "Specific Guidelines" specifically add medical service items, disease types, and disease diagnosis related groups on the basis of traditional departments, consultations, and bed-day cost accounting.
-
FDA expands the eligibility of new crown vaccines for enhanced injections and officially approves the use of mixed sequential enhanced injections
Time of Update: 2021-12-05
The FDA has determined that for people 18 years and older, the benefits of using a single booster dose of Moderna or Pfizer-BioNTech new crown vaccine after completing primary vaccination exceed the risk of developing myocarditis and pericarditis, in order to provide protection against new coronary pneumonia and its related seriousness.
-
ADC track: 14 global listings, domestic pharmaceutical companies usher in harvest
Time of Update: 2021-12-05
▲The R&D pipeline of Rongchang Biological (data of products under research as of June 30, 2021) Source: Company Financial Report In addition, the ADC drug research and development of other domestic pharmaceutical companies is gradually entering the harvest period .
-
State Drug Administration "Administrative Measures for Monitoring and Re-evaluation of Medical Device Adverse Events (Draft Amendment)" (Draft for Solicitation of Comments) Notice of Public Solicitation of Comments
Time of Update: 2021-12-05
State Drug Administration November 23 2021 "Administrative Measures for Monitoring and Re-evaluation of Medical Device Adverse Events (Draft Amendment)" (Draft for Solicitation of Comments).
docx"Administrative Measures for Monitoring and Re-evaluation of Medical Device Adverse Events (Draft Amendment)" (Draft for Solicitation of Comments).
-
The Center for Drug Evaluation issued the "Guiding Principles for Clinical Research and Development of Anti-tumor Drugs Oriented by Clinical Value"
Time of Update: 2021-12-05
In order to implement the clinical value-oriented and patient-centered R&D concept, and promote the scientific and orderly development of anti-tumor drugs, under the deployment of the National Medical Products Administration, the Center for Drug Evaluation has organized and formulated the "Clinical Value-Oriented Anti-tumor Drugs" Guidelines for Clinical Research and Development of Tumor Drugs (see appendix) .
-
Over 1 billion U.S. dollars to help develop RNAi therapy GSK for the treatment of NASH reached a cooperation
Time of Update: 2021-12-05
Today, Arrowhead Pharmaceuticals announced that it has reached a cooperation agreement with GlaxoSmithKline (GSK) to jointly develop and promote its research RNAi therapy ARO-HSD for the treatment of non-alcoholic steatohepatitis (NASH) .
-
Facing the challenge of "no medicines available", a new wave of RSV drugs in research is progressing!
Time of Update: 2021-12-04
Globally, there are a number of preventive vaccines and innovative drugs for respiratory diseases caused by RSV that are already in the clinical development stage, which is expected to usher in a new dawn .
-
Benefiting from COVID-19 drugs and vaccines, Pfizer's revenue is expected to exceed 100 billion next year
Time of Update: 2021-12-04
According to Pfizer's 2021 third-quarter financial report, the total sales revenue of the new crown vaccine Comirnaty in the third quarter was nearly 13 billion U.
In addition to the new COVID-19 antiviral market opportunity, Pfizer has already received tens of billions of dollars in revenue through Comirnaty .